NuCana (NASDAQ:NCNA) had its price objective lowered by HC Wainwright from $10.00 to $9.00 in a research report released on Wednesday, PriceTargets.com reports. The brokerage currently has a buy rating on the stock.
Separately, Zacks Investment Research lowered NuCana from a hold rating to a sell rating in a report on Wednesday.
Shares of NASDAQ NCNA opened at $2.84 on Wednesday. The firm has a market cap of $148.14 million, a price-to-earnings ratio of -2.51 and a beta of 0.72. The firm’s 50-day moving average is $2.51. NuCana has a 52 week low of $1.88 and a 52 week high of $7.83.
Several hedge funds have recently made changes to their positions in NCNA. Geode Capital Management LLC bought a new stake in shares of NuCana in the 1st quarter worth approximately $72,000. HRT Financial LP bought a new stake in shares of NuCana in the 1st quarter worth approximately $109,000. Traynor Capital Management Inc. bought a new stake in shares of NuCana in the 2nd quarter worth approximately $30,000. Monashee Investment Management LLC bought a new stake in shares of NuCana in the 2nd quarter worth approximately $554,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of NuCana in the 2nd quarter worth approximately $59,000. Institutional investors own 40.67% of the company’s stock.
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
Featured Article: Stop Order Uses For Individual Investors
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.